Considerations for use of SARS-CoV-2 antigen testing in nursing homes
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

i

Up-to-date Information

Up-to-Date Info: To find the latest CDC information on this topic go to: https://www.cdc.gov/coronavirus/2019-ncov/index.html

Considerations for use of SARS-CoV-2 antigen testing in nursing homes

Filetype[PDF-224.16 KB]


  • English
    • Details Supporting Files You May Also Like

    Details:

    • Corporate Authors:
      National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
    • Description:
      Updated Oct. 23, 2020

      This document provides a summary of considerations for use of SARS-CoV-2 (the virus that causes COVID-19) antigen testing in nursing homes and is intended for nursing home providers and state and local public health departments.

      Antigen tests are available as point-of-care (POC) diagnostics for SARS-CoV-2. They have a rapid turnaround time, which is critical to the identification of SARS-CoV-2 infection and rapid implementation of infection prevention and control strategies. These tests can augment other testing efforts, especially in settings where RT-PCR testing capacity is limited or testing results are delayed (e.g., >48 hours). In general, these POC antigen tests have a lower sensitivity, but similar specificity, for detecting SARS-CoV-2 compared to reverse-transcriptase polymerase chain reaction (RT-PCR) tests.

      This document pertains to antigen tests that have been granted a US Food and Drug Administration’s Emergency Use Authorization (FDA EUA) to detect SARS-CoV-2. The first two SARS-CoV-2 antigen tests to receive FDA EUA are authorized for testing symptomatic persons within 5 days of symptom onset and there are limited data on antigen test performance in asymptomatic persons. However, given the transmission of SARS-CoV-2 from asymptomatic and presymptomatic nursing home residents and healthcare personnel (HCP) with SARS-CoV-2 infection, CDC is providing considerations for the use of antigen tests in asymptomatic persons during this public health emergency. Facilities should be aware of the FDA EUAexternal icon for antigen testsexternal icon and potential implications for the Clinical Laboratory Improvement Amendments (CLIA)external icon certificate of waiver when using antigen tests in asymptomatic individuals and in persons >5 days from symptom onset.

    • Content Notes:
      Overview of Testing for SARS-CoV-2 -- Interim Guidance for Rapid Antigen Testing for SARS-CoV-2 -- Interim SARS-CoV-2 Testing Guidelines for Nursing Home Residents and Healthcare Personnel -- Interim Guidance on Testing Healthcare Personnel for SARS-CoV-2 -- Interpreting Results of Diagnostic Tests.
    • Subjects:
    • Document Type:
      Webpage
    • Genre:
      Guideline
    • Place as Subject:
      United States
    • Collection(s):
    • Main Document Checksum:
    • Download URL:
    • File Type:

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov